(Total Views: 157)
Posted On: 08/09/2023 5:03:05 PM
Post# of 104
NetworkNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Positive Efficacy Results from Clinical Study of NoStingz
Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced data from a recent clinical study of NoStingz, its proprietary topical sunscreen formulated to protect users from jellyfish, sea lice and UVA/UVB rays. According to the update, Portuguese man-o’-war (“MOW”), a marine hydrozoan closely related to jellyfish, has a powerful sting that has been known to kill humans. The present study used MOW gathered from the Atlantic Ocean near Key West, Florida, in 51 trials conducted testing three sunscreen compounds, including NoStingz, against control. Reportedly, the NoStingz area of the participants’ arms had a statistically significant lower pain score than control and both of the other sunscreens tested. “This latest data confirms prior clinical study results and what we’ve been hearing from happy customers about NoStingz—it works,” said Jupiter Wellness CEO Brian John. “These results will support the expansion of our sales channels for NoStingz as well providing important insight into making further advancements with our sunscreen and skin care product lines.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced data from a recent clinical study of NoStingz, its proprietary topical sunscreen formulated to protect users from jellyfish, sea lice and UVA/UVB rays. According to the update, Portuguese man-o’-war (“MOW”), a marine hydrozoan closely related to jellyfish, has a powerful sting that has been known to kill humans. The present study used MOW gathered from the Atlantic Ocean near Key West, Florida, in 51 trials conducted testing three sunscreen compounds, including NoStingz, against control. Reportedly, the NoStingz area of the participants’ arms had a statistically significant lower pain score than control and both of the other sunscreens tested. “This latest data confirms prior clinical study results and what we’ve been hearing from happy customers about NoStingz—it works,” said Jupiter Wellness CEO Brian John. “These results will support the expansion of our sales channels for NoStingz as well providing important insight into making further advancements with our sunscreen and skin care product lines.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
